Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 202 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffered Injection Clear all
Available No phase listed Expanded access

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

NCT01487044
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

NCT00800605
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

NCT01487070
View directory record Official record
Conditions
PDR
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 22, 2026, 6:11 PM EDT
Recruiting Phase 1 Interventional

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

NCT07158905
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease
Interventions
AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
Biological · Other
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
65 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

NCT00768066
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia

NCT02209272
View directory record Official record
Conditions
Hip Pain
Interventions
bacteriostatic saline, buffered lidocaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01542034
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognitive, Emotional, and Neural Responses to Acute Inflammation

NCT03294564
View directory record Official record
Conditions
Healthy
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
11,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients

NCT01622296
View directory record Official record
Conditions
Pain
Interventions
Sodium bicarbonate, Lidocaine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
9 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

NCT02035267
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
Deoxycholic Acid, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
VCL-HB01, VCL-HM01, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 22, 2026, 6:11 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA®4 for Midface Volume Deficiency

NCT05133739
View directory record Official record
Conditions
Cheek Augmentation, Correction of Age-related Midface Contour Deficiencies
Interventions
injection of RHA®4 in Midface, injection of Comparator Product in Midface
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 22, 2026, 6:11 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Block for Pain Control With Osmotic Dilator Placement

NCT02354092
View directory record Official record
Conditions
Abortion Late, Pain
Interventions
Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control
Procedure · Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine

NCT02747186
View directory record Official record
Conditions
Anesthesia
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis

NCT02588872
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Platelet-rich Plasma (PRP), Hyaluronic Acid
Biological
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine

NCT02776761
View directory record Official record
Conditions
Hantaan Virus
Interventions
Hantaan Vaccine:, Puumala Vaccine, Hantaan/Puumala Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Subcutaneous Injection in Healthy Participants

NCT06516913
View directory record Official record
Conditions
Healthy
Interventions
Harvard Apparatus syringe pump
Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
22 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 22, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 22, 2026, 6:11 PM EDT